

*Entail*  
Glu,

wherein at least one of the following conditions (I)-(V) is true:

I) at least one of  $X_4$ ,  $X_5$ ,  $X_6$ , Thr, Lys, and Arg is independently substituted with a non-natural or unusual amino acid,

II) the polypeptide is cyclized,

III) the polypeptide is stabilized,

IV) the aminoterminal amino acid residue is acylated, or

V) the carboxyterminal amino acid residue is amidated,

if the polypeptide is not cyclized, said sequence SEQ ID NO:19 corresponding essentially to the C-terminal of said polypeptide,

said polypeptide having at least one of the following properties:

a) induces inhibition of spontaneous IL-8 production by human monocytes,

b) induces inhibition of IL-1 $\beta$  induced IL-8 production by human peripheral blood mononuclear cells (PBMC),

c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,

d) induces chemotactic migration of CD8+ human T lymphocytes in vitro,

e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,

f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,

g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,

h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN- $\gamma$ ,

i) induces the production of IL-4 by cultured normal human CD4+ T cells,

j) reduces [the] TNF $\alpha$  production in human mixed leukocyte reaction, or

k) downregulates TNF $\alpha$  and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces

*D30120121*  
neutrophil infiltration in the lungs of the treated rabbits.

Please add the following new claims:

--65. The polypeptide of claim 18 where SEQ ID NO:19 is the C-terminal of said polypeptide and the polypeptide is not cyclized.

66. The polypeptide of claim 65 which has a length of up to about 20 amino acids.

67. The polypeptide of claim 66 whose length does not exceed 10 amino acids.

*D4*  
68. The polypeptide of claim 18, said polypeptide being selected from the group consisting of polypeptides identical to SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22, except that at least one of conditions (I)-(V) applies.

69. The method of claim 49 which is a method of treating a disease.

70. The method of claim 69 where the disease involves pro-inflammatory activities.

71. The method of claim 69 where the disease is one inhibited by IL-10.

72. The method of claim 69 where the disease is one caused or aggravated by IL-8, MCAF or IL-1.--

#### REMARKS

##### 1. General Matters

1.1. As a result of this amendment, claims 18-72 are pending.

1.2. The Examiner is thanked for reconsidering the group restriction. If a generic claim is allowed, or is allowable in substance, the species restriction should be reconsidered, pursuant to MPEP §809.02(c)(B) and 809.02(e).

1.3. A \$120 reference to PCT/DK97/00021 has been added.

1.4. The "Figure legends" have been retitled and relocated.

1.5. An abstract has been added.

##### 2. Product of Nature Issues